A new Perspective in npj Vaccines, co-authored and jointly supervised by NAVIPP-supported researcher Piero Olliaro, explores how future Nipah vaccines and treatments could be used in outbreak settings—and what this means for their development.

Developing a promising medicine is one part of outbreak preparedness. Researchers also need to understand who would receive it, when it would be administered, and whether health services could deliver it where it is needed.

Published on 4 November 2026, Stakeholder-informed use cases and target product characteristics for vaccines and therapeutics for Nipah virus disease addresses these questions through an international expert consultation.

The two-day meeting in New Delhi brought together more than 40 participants from public health agencies, regulatory bodies, research institutions and product development organisations. It was co-organised by the Coalition for Epidemic Preparedness Innovations (CEPI), the Indian Council of Medical Research (ICMR) and ISARIC, with funding from CEPI.

Planning for complementary tools

Participants explored potential uses for vaccines, monoclonal antibodies and small-molecule therapeutics across different outbreak scenarios and stages.

The resulting framework distinguishes their potential roles: vaccines for prevention; monoclonal antibodies for immediate protection after exposure and potentially early treatment; and small-molecule therapeutics for treatment or prevention, depending on the evidence available for each product.

These distinctions have practical implications. How quickly must protection begin? What route of administration would be feasible? What storage requirements, costs and delivery constraints could limit access?

Addressing such questions early can help align product development with the needs of affected populations and health services.

The connection with NAVIPP

The publication explicitly acknowledges NAVIPP support for Professor Piero Olliaro at the University of Oxford, through UK Research and Innovation’s Horizon Europe funding guarantee. Olliaro jointly supervised the work and co-led the drafting of the manuscript.

The framework is particularly relevant to NAVIPP’s Work Package 5, which includes developing a draft target product profile for Nipah antivirals for submission to WHO. Such profiles translate public health needs into the characteristics developers should aim to achieve.

The publication offers a useful foundation for this work by connecting possible uses of future products with their development requirements.

A foundation for further research

The proposed use cases draw on expert consultation and hypothetical product profiles. They require further validation and adaptation to local contexts, including greater input from affected communities and frontline implementers.

The central message is clear: preparations for future Nipah countermeasures should bring together product development, clinical research readiness and equitable access before the next outbreak.

Read the publication in npj Vaccines

NAVIPP is funded by the European Union under grant agreement No. 101137506, with support for UK participation from UKRI.